Dianthus Therapeutics 320% Year: What Investors Should Know as Stakes Shift
Dianthus Therapeutics has surged 320% over the past year, even as a large investor reduced its stake. This article di...
Deciding whether zero based or traditional budgeting is better depends on your financial goals. Explore both to find the right fit for you.
25,778 articlesDianthus Therapeutics has surged 320% over the past year, even as a large investor reduced its stake. This article di...
A volatile week left crypto ETFs in the red while a memory-chip ETF seized the spotlight, signaling a shift in invest...
A Manhattan bar tests risk hedging during the NBA Finals, using Kalshi to cover tabs if the Knicks win, after a costl...
Bark is shaping its path in a competitive pet market. This guide breaks down what to expect in bark (bark) 2026 earni...
June delivered a mix of headlines and price moves that kept traders on their toes. Robinhood’s 10% workforce cut alon...
SpaceX remains privately held, but chatter about a public listing fuels the myth that a superstar IPO will power the ...
A July 2026 mid-year review spots Coca-Cola, Procter & Gamble, and Johnson & Johnson as the leading dividend aristocr...
Set a weekly ritual to translate headlines into a smarter portfolio. This Thursday reads guide shows you how to pick ...
Rocket Lab shares hover near $67 as July odds tilt toward downside. This story breaks down what prediction markets be...
A major biotech fund has increased its stake in Scholar Rock, increasing exposure to a platform that targets protein ...
February delivered a sharp setback for AMZN as investors weighed another wave of capital spending against growth pros...
Two new lawsuits filed by Anthropic target the Department of Defense, arguing for stricter controls on how its Claude...